drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous cellular immunotherapy)
drug_description
Autologous CAR T-cell therapy in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor targeting GPRC5D; upon antigen engagement, CAR signaling (CD3ζ with co-stimulation) activates T cells to proliferate and kill GPRC5D-expressing myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting GPRC5D; upon antigen binding, CD3ζ and co-stimulatory signaling activate and expand the T cells, driving cytokine release and perforin/granzyme-mediated killing of GPRC5D-positive myeloma cells.
drug_name
DeepTag-GPRC5D Targeted CAR T-cells
nct_id_drug_ref
NCT06084962